Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at email@example.com.
Articles by Eric Palmer
Next year, Merck KGaA plans to start a biomass heating plant in the U.S. but for now is starting on a project in India that will use cashew and coconut shells, recycling a local waste product into biomass fuel.
India's Aurobindo has recalled a lot of an epilepsy drug because some of the capsules contain no drug at all.
NewLink Genetics, the small Iowa company working on a promising Ebola vaccine, has been looking for manufacturing muscle, not to mention development experience and marketing know-how, to get its Ebola vaccine to market.
For the second time in four months, Baxter International finds itself recalling highly concentrated potassium chloride. This time it's a labeling problem, one that the company says has the potential to be life-threatening.
When AbbVie announced its plans for a $320 million bulk manufacturing facility in Singapore in February, it said it would be its first in Asia when it was ready to roll near the end of the decade. But the drugmaker has now picked up a smaller API plant in Singapore and it will be up and running in 2016.
Bristol-Myers Squibb announced a new project in Ireland earlier this month, followed by Amgen's completion of a continuous processing facility in Singapore. Now AstraZeneca says it needs more biologics capacity and will spend in excess of $200 million to build out a facility in Maryland.
In March, Hospira announced it had reached a $60 million agreement to settle a three-year-old lawsuit that said investors had been kept in the dark about the quality problems at its manufacturing operations. But another suit was filed last June, and now the Lake Forest, IL, company says it has been rolled into the settlement.
A U.S. federal judge has turned down Ranbaxy Laboratories' request for a temporary restraining order against the FDA after the agency revoked the Indian drugmaker's approvals to make generics of AstraZeneca's blockbuster Nexium and Roche's antiviral Valcyte because of its manufacturing shortcomings.
Amgen CEO Robert Bradway hinted several years ago that the company was on the "cusp" of a new manufacturing process for making cell-based drugs that would upend the industry, being faster and cheaper. Today, Amgen said that time has arrived, with completion in Singapore of a $200 million plant that incorporates continuous processing.
A U.S. oncologist who thought he was getting a great deal on drugs that were almost the same thing as Avastin has found they will cost him an extra $2 million and a federal misdemeanor conviction.